Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals

Ulrich P. Jorde, Harold W. Horowitz, Gary P. Wormser

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: To determine the safety and efficacy of 100 mg dapsone three times weekly for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected, trimethoprim-sulfamethoxazole (TMP-SMX)-intolerant patients. Design: Retrospective chart review of patients followed-up to 22 May 1992. Setting: Infectious diseases outpatient clinic of a tertiary care center in suburban New York City. Patients: Twenty-three HIV-infected patients requiring PCP prophylaxis with documented intolerance to TMP-SMX. Main outcome measures: Patients were followed clinically and with laboratory testing at approximately monthly intervals. Results: Dapsone was discontinued in nine (39%) patients because of adverse reactions. All reactions occurred within the first 2 months of treatment. Two (14%) of the remaining 14 patients developed histologically proven PCP over 126 patient-months of follow-up. Conclusion: Approximately 40% of TMP-SMX-intolerant HIV-infected individuals are also intolerant of dapsone. Prophylaxis failures may be expected on a dose regimen of 100 mg dapsone three times weekly. More experience with other dose regimens and alternative agents is needed.

Original languageEnglish (US)
Pages (from-to)355-359
Number of pages5
JournalAIDS
Volume7
Issue number3
StatePublished - Mar 1993
Externally publishedYes

Fingerprint

Dapsone
Pneumocystis Pneumonia
Sulfamethoxazole Drug Combination Trimethoprim
HIV
Ambulatory Care Facilities
Tertiary Care Centers
Communicable Diseases
Outcome Assessment (Health Care)
Safety

Keywords

  • Cross-reactivity
  • Dapsone
  • HIV
  • Intolerance
  • Pneumocystis carinii
  • Trimethoprim-sulfamethoxazole

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. / Jorde, Ulrich P.; Horowitz, Harold W.; Wormser, Gary P.

In: AIDS, Vol. 7, No. 3, 03.1993, p. 355-359.

Research output: Contribution to journalArticle

@article{5753c041a80240d485211e92ba84695c,
title = "Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals",
abstract = "Objective: To determine the safety and efficacy of 100 mg dapsone three times weekly for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected, trimethoprim-sulfamethoxazole (TMP-SMX)-intolerant patients. Design: Retrospective chart review of patients followed-up to 22 May 1992. Setting: Infectious diseases outpatient clinic of a tertiary care center in suburban New York City. Patients: Twenty-three HIV-infected patients requiring PCP prophylaxis with documented intolerance to TMP-SMX. Main outcome measures: Patients were followed clinically and with laboratory testing at approximately monthly intervals. Results: Dapsone was discontinued in nine (39{\%}) patients because of adverse reactions. All reactions occurred within the first 2 months of treatment. Two (14{\%}) of the remaining 14 patients developed histologically proven PCP over 126 patient-months of follow-up. Conclusion: Approximately 40{\%} of TMP-SMX-intolerant HIV-infected individuals are also intolerant of dapsone. Prophylaxis failures may be expected on a dose regimen of 100 mg dapsone three times weekly. More experience with other dose regimens and alternative agents is needed.",
keywords = "Cross-reactivity, Dapsone, HIV, Intolerance, Pneumocystis carinii, Trimethoprim-sulfamethoxazole",
author = "Jorde, {Ulrich P.} and Horowitz, {Harold W.} and Wormser, {Gary P.}",
year = "1993",
month = "3",
language = "English (US)",
volume = "7",
pages = "355--359",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals

AU - Jorde, Ulrich P.

AU - Horowitz, Harold W.

AU - Wormser, Gary P.

PY - 1993/3

Y1 - 1993/3

N2 - Objective: To determine the safety and efficacy of 100 mg dapsone three times weekly for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected, trimethoprim-sulfamethoxazole (TMP-SMX)-intolerant patients. Design: Retrospective chart review of patients followed-up to 22 May 1992. Setting: Infectious diseases outpatient clinic of a tertiary care center in suburban New York City. Patients: Twenty-three HIV-infected patients requiring PCP prophylaxis with documented intolerance to TMP-SMX. Main outcome measures: Patients were followed clinically and with laboratory testing at approximately monthly intervals. Results: Dapsone was discontinued in nine (39%) patients because of adverse reactions. All reactions occurred within the first 2 months of treatment. Two (14%) of the remaining 14 patients developed histologically proven PCP over 126 patient-months of follow-up. Conclusion: Approximately 40% of TMP-SMX-intolerant HIV-infected individuals are also intolerant of dapsone. Prophylaxis failures may be expected on a dose regimen of 100 mg dapsone three times weekly. More experience with other dose regimens and alternative agents is needed.

AB - Objective: To determine the safety and efficacy of 100 mg dapsone three times weekly for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected, trimethoprim-sulfamethoxazole (TMP-SMX)-intolerant patients. Design: Retrospective chart review of patients followed-up to 22 May 1992. Setting: Infectious diseases outpatient clinic of a tertiary care center in suburban New York City. Patients: Twenty-three HIV-infected patients requiring PCP prophylaxis with documented intolerance to TMP-SMX. Main outcome measures: Patients were followed clinically and with laboratory testing at approximately monthly intervals. Results: Dapsone was discontinued in nine (39%) patients because of adverse reactions. All reactions occurred within the first 2 months of treatment. Two (14%) of the remaining 14 patients developed histologically proven PCP over 126 patient-months of follow-up. Conclusion: Approximately 40% of TMP-SMX-intolerant HIV-infected individuals are also intolerant of dapsone. Prophylaxis failures may be expected on a dose regimen of 100 mg dapsone three times weekly. More experience with other dose regimens and alternative agents is needed.

KW - Cross-reactivity

KW - Dapsone

KW - HIV

KW - Intolerance

KW - Pneumocystis carinii

KW - Trimethoprim-sulfamethoxazole

UR - http://www.scopus.com/inward/record.url?scp=0027533725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027533725&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 355

EP - 359

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -